Covaxin 77.8% Effective In Phase 3 Trial Data: Sources

<!–

–>

Covaxin 77.8% Effective In Phase 3 Trial Data Reviewed By Expert Committee: Sources

New Delhi:

Bharat Biotech’s Covaxin is 77.8 per cent effective in protecting against COVID-19 according to results of Phase III trial data approved by the DCGI’s Subject Expert Committee, source said this afternoon.

Related posts

Leave a Comment